Biotech Startups

SaniSure develops Mixed4Sure, a single-use mixing platform for small-volume biopharmaceutical processing that handles volumes from 50 mL to 20 L with reduced shear forces and lower capital costs than traditional stainless-steel systems.

1 investor

Sanmirna Therapeutics develops microRNA-targeted therapeutics for cancer treatment, with its lead candidate Miristen™ currently in Phase I clinical trials for acute myeloid leukemia. The company leverages microRNA discovery to create novel oncology treatments.

1 investor

Sanos provides clinical trial management services for pharmaceutical sponsors across multiple therapeutic areas, offering end-to-end capabilities from protocol development through regulatory approval. The company operates as a strategic partner for drug development, managing patient recruitment, data integrity, and operational execution with fixed budgets and timelines.

1 investor

SANSHO Co., Ltd. is a Japanese drug-development company creating pharmaceuticals based on cyclic phosphatidic acid (cPA), including 2-carba-cyclic phosphatidic acid candidates in clinical trials for knee osteoarthritis and pulmonary fibrosis. The company conducts research and development to bring these medicines to clinical use.

1 investor

Santa Ana Bio is a biotech company developing engineered antibody therapeutics that target the immune pathways and cells driving autoimmune and inflammatory diseases. It is building a pipeline of first-in-class and best-in-class biologics for conditions such as inflammatory bowel disease and scleroderma-associated interstitial lung disease.

1 investor

Santero is a Belgium-based biotech company developing antibacterial drugs, including an RSH inhibitor programme targeting Pseudomonas aeruginosa and multidrug-resistant pathogens. It runs drug discovery and preclinical development spanning computational chemistry, medicinal chemistry, and screening toward clinical development.

1 investor

Saol Therapeutics is a clinical-stage pharmaceutical company focused on developing therapies for CNS disorders, pain conditions, and orphan diseases. The company recently divested its commercial assets to concentrate on advancing its pipeline of late-stage clinical programs.

1 investor

Sapala Organics is a contract research and manufacturing organization (CRO/CDMO) specializing in nucleic acid chemistry, oligonucleotide synthesis, and medicinal chemistry for the pharmaceutical industry. Now a subsidiary of Cohance Lifesciences, the company provides drug discovery and development services focused on genetic therapies and complex small molecule synthesis.

1 investor

Sarcio Inc. is a University of Minnesota Stem Cell Institute spin-out developing regenerative, disease-modifying therapeutics by isolating exosomes from iPSC-derived cartilage tissue to treat osteoarthritis and restore joint function. The company aims to delay or eliminate the need for joint-replacement surgery.

1 investor

The company develops cancer immunotherapy treatments. Based on the team composition and mission statement, it operates in the biotech and healthcare sectors.

1 investor

Sarsia is a venture capital and investment firm that backs early-stage companies in life sciences, technology, energy, and sustainability sectors. The firm draws on a team with academic and industry expertise spanning biology, physics, engineering, pharmacology, and finance.

1 investor

Sauvie is developing a protein discovery platform in the biological intelligence space. The company's website is a pre-launch placeholder with limited details.

1 investor

Sayre Therapeutics is a pharmaceutical company operating across India, South Asia, and Southeast Asia that distributes differentiated global drugs and treatments for rare and orphan diseases to emerging markets. The company brings novel medical solutions to patients and clinicians in oncology and rare disease care.

1 investor

SB TEMPUS supports personalized medicine for cancer treatment by integrating medical data and AI. The company offers genetic testing, medical data utilization, and AI applications serving healthcare institutions, pharmaceutical companies, and biotech ventures.

1 investor

SCA Pharma is a 503B outsourcing facility that compounds and supplies sterile medications to hospitals and pharmacies, helping fill inventory gaps caused by supply chain disruptions. It serves healthcare providers and pharmacy leaders in the pharmaceutical supply industry.

1 investor

SCAI Therapeutics develops pharmaceutical and cosmetic products based on its proprietary platform technology, MOASIS. The company is a startup based in South Korea.

1 investor

Scale Biosciences develops patented single-cell analysis technology that enables researchers to conduct massively parallelized sequencing at reduced cost. The company serves biomedical research labs seeking to study complex cell biology at scale.

1 investor

Scancell is a late-stage clinical biotechnology company developing active immunotherapies to strengthen anti-tumor immune responses in hard-to-treat cancers. Its treatments are built on its proprietary Immunobody and Moditope platforms.

1 investor

ScandiBio Therapeutics is a biotechnology company developing therapeutics based on research from leading Swedish and UK academic institutions. The company was founded by researchers from KTH Royal Institute of Technology, Karolinska Institutet, Sahlgrenska Academy, and King's College London.

1 investor

SCD Probiotics develops a fermentation-based biological platform that grows multiple microbial strains together into consortia to produce probiotics and microbial biochemicals. Its products serve applications ranging from gut and home health to industrial uses such as leather processing, offering bio-based, non-toxic alternatives to petroleum-based chemicals.

1 investor

Clinical-stage biopharmaceutical company focused on discovery and development of innovative medicines for serious diseases by targeting the Transforming Growth Factor Beta pathway.

1 investor

Schrödinger develops a physics-based computational platform for discovering and optimizing molecules, used to accelerate drug discovery and materials design. The company also operates a therapeutics group that pursues drug development on validated targets and offers educational resources for the field.

1 investor

Dr. Willmar Schwabe is a family-owned pharmaceutical company that researches, develops, and manufactures herbal medicines (phytopharmaceuticals) derived from plants, controlling the full production process from planting to packaging. Its products are sold through pharmacies and manufactured in Germany.

1 investor

Scieline provides a data management and R&D workflow platform for research teams in biotech, chemistry, and food & beverage sectors to streamline experiment design, execution, and data capture. The platform replaces paper-based and spreadsheet-driven research with automated, governed data management and process-driven tools.

1 investor